Chunbo Chen1, Xiaobing Yang2, Ying Lei2, Yan Zha3, Huafeng Liu4, Changsheng Ma5, Jianwei Tian2, Pingyan Chen2, Tiecheng Yang6, Fan Fan Hou7. 1. Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangzhou, China; Department of Critical Care Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China; 2. Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangzhou, China; 3. Department of Nephrology, Guizhou Provincial People's Hospital, Guiyang Medical University, Guiyang, China; 4. Division of Nephrology, Institute of Nephrology, Guangdong Medical College, Zhanjiang, China; 5. Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China; and. 6. Division of Nephrology, The Futian Hospital, Guangdong Medical College, Shenzhen, China. 7. Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangzhou, China; ffhouguangzhou@163.com.
Abstract
BACKGROUND AND OBJECTIVES: A major challenge in early treatment of acute cardiorenal syndrome (CRS) is the lack of predictors for progression of AKI. We aim to investigate the utility of urinary angiotensinogen and other renal injury biomarkers in predicting AKI progression in CRS. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: In this prospective, multicenter study, we screened 732 adults who admitted for acute decompensated heart failure from September 2011 to December 2014, and evaluated whether renal injury biomarkers measured at time of AKI diagnosis can predict worsening of AKI. In 213 patients who developed Kidney Disease Improving Global Outcomes stage 1 or 2 AKI, six renal injury biomarkers, including urinary angiotensinogen (uAGT), urinary neutrophil gelatinase-associated lipocalin (uNGAL), plasma neutrophil gelatinase-associated lipocalin, urinary IL-18 (uIL-18), urinary kidney injury molecule-1, and urinary albumin-to-creatinine ratio, were measured at time of AKI diagnosis. The primary outcome was AKI progression defined by worsening of AKI stage (50 patients). The secondary outcome was AKI progression with subsequent death (18 patients). RESULTS: After multivariable adjustment, the highest tertile of three urinary biomarkers remained associated with AKI progression compared with the lowest tertile: uAGT (odds ratio [OR], 10.8; 95% confidence interval [95% CI], 3.4 to 34.7), uNGAL (OR, 4.7; 95% CI, 1.7 to 13.4), and uIL-18 (OR, 3.6; 95% CI, 1.4 to 9.5). uAGT was the best predictor for both primary and secondary outcomes with area under the receiver operating curve of 0.78 and 0.85. These three biomarkers improved risk reclassification compared with the clinical model alone, with uAGT performing the best (category-free net reclassification improvement for primary and secondary outcomes of 0.76 [95% CI, 0.46 to 1.06] and 0.93 [95% CI, 0.50 to 1.36]; P<0.001). Excellent performance of uAGT was further confirmed with bootstrap internal validation. CONCLUSIONS: uAGT, uNGAL, and uIL-18 measured at time of AKI diagnosis improved risk stratification and identified CRS patients at highest risk of adverse outcomes.
BACKGROUND AND OBJECTIVES: A major challenge in early treatment of acute cardiorenal syndrome (CRS) is the lack of predictors for progression of AKI. We aim to investigate the utility of urinary angiotensinogen and other renal injury biomarkers in predicting AKI progression in CRS. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: In this prospective, multicenter study, we screened 732 adults who admitted for acute decompensated heart failure from September 2011 to December 2014, and evaluated whether renal injury biomarkers measured at time of AKI diagnosis can predict worsening of AKI. In 213 patients who developed Kidney Disease Improving Global Outcomes stage 1 or 2 AKI, six renal injury biomarkers, including urinary angiotensinogen (uAGT), urinary neutrophil gelatinase-associated lipocalin (uNGAL), plasma neutrophil gelatinase-associated lipocalin, urinary IL-18 (uIL-18), urinary kidney injury molecule-1, and urinary albumin-to-creatinine ratio, were measured at time of AKI diagnosis. The primary outcome was AKI progression defined by worsening of AKI stage (50 patients). The secondary outcome was AKI progression with subsequent death (18 patients). RESULTS: After multivariable adjustment, the highest tertile of three urinary biomarkers remained associated with AKI progression compared with the lowest tertile: uAGT (odds ratio [OR], 10.8; 95% confidence interval [95% CI], 3.4 to 34.7), uNGAL (OR, 4.7; 95% CI, 1.7 to 13.4), and uIL-18 (OR, 3.6; 95% CI, 1.4 to 9.5). uAGT was the best predictor for both primary and secondary outcomes with area under the receiver operating curve of 0.78 and 0.85. These three biomarkers improved risk reclassification compared with the clinical model alone, with uAGT performing the best (category-free net reclassification improvement for primary and secondary outcomes of 0.76 [95% CI, 0.46 to 1.06] and 0.93 [95% CI, 0.50 to 1.36]; P<0.001). Excellent performance of uAGT was further confirmed with bootstrap internal validation. CONCLUSIONS: uAGT, uNGAL, and uIL-18 measured at time of AKI diagnosis improved risk stratification and identified CRSpatients at highest risk of adverse outcomes.
Authors: Markku S Nieminen; Michael Böhm; Martin R Cowie; Helmut Drexler; Gerasimos S Filippatos; Guillaume Jondeau; Yonathan Hasin; José Lopez-Sendon; Alexandre Mebazaa; Marco Metra; Andrew Rhodes; Karl Swedberg; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin R Cowie; Veronica Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; Maria Angeles Alonso Garcia; Kenneth Dickstein; Anibal Albuquerque; Pedro Conthe; Maria Crespo-Leiro; Roberto Ferrari; Ferenc Follath; Antonello Gavazzi; Uwe Janssens; Michel Komajda; João Morais; Rui Moreno; Mervyn Singer; Satish Singh; Michal Tendera; Kristian Thygesen Journal: Eur Heart J Date: 2005-01-28 Impact factor: 29.983
Authors: Andrew K Roy; Catherine Mc Gorrian; Cecelia Treacy; Edel Kavanaugh; Alice Brennan; Niall G Mahon; Patrick T Murray Journal: Cardiorenal Med Date: 2013-02-26 Impact factor: 2.041
Authors: Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Heather Thiessen-Philbrook; Aldo J Peixoto; Mark A Perazella; Naheed Ansari; Joseph Lim; Steven G Coca; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2014-09-02 Impact factor: 8.237
Authors: Edward D Siew; T Alp Ikizler; Tebeb Gebretsadik; Ayumi Shintani; Nancy Wickersham; Frederick Bossert; Josh F Peterson; Chirag R Parikh; Addison K May; Lorraine B Ware Journal: Clin J Am Soc Nephrol Date: 2010-06-17 Impact factor: 8.237
Authors: Jay L Koyner; Vishal S Vaidya; Michael R Bennett; Qing Ma; Elaine Worcester; Shahab A Akhter; Jai Raman; Valluvan Jeevanandam; Micheal F O'Connor; Prasad Devarajan; Joseph V Bonventre; Patrick T Murray Journal: Clin J Am Soc Nephrol Date: 2010-08-26 Impact factor: 8.237
Authors: Isaac E Hall; Sri G Yarlagadda; Steven G Coca; Zhu Wang; Mona Doshi; Prasad Devarajan; Won K Han; Richard J Marcus; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2009-09-17 Impact factor: 10.121
Authors: Michael Haase; Christian Müller; Kevin Damman; Patrick T Murray; John A Kellum; Claudio Ronco; Peter A McCullough Journal: Contrib Nephrol Date: 2013-05-13 Impact factor: 1.580
Authors: John M Arthur; Elizabeth G Hill; Joseph L Alge; Evelyn C Lewis; Benjamin A Neely; Michael G Janech; James A Tumlin; Lakhmir S Chawla; Andrew D Shaw Journal: Kidney Int Date: 2013-09-04 Impact factor: 10.612
Authors: Agata Bielecka-Dabrowa; Breno Godoy; Joerg C Schefold; Michael Koziolek; Maciej Banach; Stephan von Haehling Journal: Curr Heart Fail Rep Date: 2018-08
Authors: Edmund Y M Chung; Katie Trinh; Jennifer Li; Sebastian Hayden Hahn; Zoltan H Endre; Natasha M Rogers; Stephen I Alexander Journal: Front Cardiovasc Med Date: 2022-05-20